This is a StreetInsider.com Premium Only Page

Fusion Pharmaceuticals Inc. (FUSN) – StreetInsider.com Reports

Apr 16, 2024 06:03 AM TD Cowen Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Mar 20, 2024 07:33 AM B.Riley Downgrades Fusion Pharmaceuticals (FUSN) to Neutral

Mar 20, 2024 07:20 AM Bloom Burton & Co. Downgrades Fusion Pharmaceuticals (FUSN) to Hold (3)

Mar 20, 2024 02:42 AM RBC Capital Downgrades Fusion Pharmaceuticals (FUSN) to Sector Perform

Mar 19, 2024 04:16 PM Jones Trading Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Mar 19, 2024 02:40 PM Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight

Mar 19, 2024 11:45 AM Truist Securities Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Mar 19, 2024 11:20 AM Midday movers: Nvidia, Coinbase fall; Unilever rises

Mar 19, 2024 10:47 AM William Blair Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform

Mar 19, 2024 10:28 AM Brookline Capital Markets Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Mar 19, 2024 10:05 AM Raymond James Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform

Mar 19, 2024 10:00 AM Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Mar 19, 2024 08:52 AM Wedbush Downgrades Fusion Pharmaceuticals (FUSN) to Neutral

Mar 19, 2024 06:03 AM Leerink Partners Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform

Mar 19, 2024 04:13 AM Fusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVR

Mar 4, 2024 06:58 AM Fusion Pharmaceuticals (FUSN) PT Raised to $16 at RBC Capital

Feb 16, 2024 08:45 AM Fusion Pharmaceuticals (FUSN) Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

Jan 19, 2024 04:15 PM Fusion Pharmaceuticals (FUSN) Increases ATM Agreement to $200M

Jan 4, 2024 04:06 PM Fusion Pharmaceuticals (FUSN) Announces Clinical Program and Manufacturing Updates

Dec 27, 2023 07:21 AM Raymond James Upgrades Fusion Pharmaceuticals (FUSN) to Strong Buy

Dec 27, 2023 03:19 AM Fusion Pharmaceuticals (FUSN) is 'sole remaining clinical-stage, targeted radiopharm player,' seen as takeover target - Oppenheimer

Dec 20, 2023 05:16 AM RBC Capital Starts Fusion Pharmaceuticals (FUSN) at Outperform

Nov 16, 2023 06:45 AM BWXT (BWXT) Expands Collaboration with Fusion Pharmaceuticals (FUSN) Through Strengthened Actinium Supply and Access to Generator Technology

Nov 7, 2023 07:07 AM Fusion Pharmaceuticals Inc. (FUSN) Tops Q3 EPS by 15c

Oct 16, 2023 07:50 AM Fusion Pharmaceuticals (FUSN) Appoints Jeremy Bender, Teresa Bitetti and David Meek to its Board

Sep 28, 2023 04:02 PM Oppenheimer Starts Fusion Pharmaceuticals (FUSN) at Outperform, 'Diverse Clinical-Stage Portfolio Positions FUSN as a Radiopharm Leader'

Aug 8, 2023 07:07 AM Fusion Pharmaceuticals Inc. (FUSN) Tops Q2 EPS by 1c

Jun 26, 2023 08:06 AM Fusion Pharmaceuticals (FUSN) to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Jun 23, 2023 08:25 AM Raymond James Starts Fusion Pharmaceuticals (FUSN) at Outperform; Sees 200% Upside

Jun 16, 2023 04:07 PM Fusion Pharmaceuticals Inc. (FUSN) Announces 4.78M Share Offering by Selling Stockholders

May 11, 2023 07:16 AM Fusion Pharmaceuticals Inc. (FUSN) Reports Q1 Earnings; Provides Clinical Program Updates

May 2, 2023 04:00 PM Fusion Pharmaceuticals (FUSN) Opens Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer

Apr 19, 2023 04:25 PM Fusion Pharmaceuticals (FUSN) Announces Presentation of Preclinical Data Supporting FPI-2059

Mar 20, 2023 04:05 PM Fusion Pharmaceuticals (FUSN) Reports First Patient Dosed in Phase 1 Study of FPI-2059

Mar 16, 2023 04:11 PM Fusion Pharmaceuticals Inc. (FUSN) Announces 17.65M Share Offering by Selling Stockholders

Mar 16, 2023 01:58 PM Fusion Pharmaceuticals (FUSN) PT Raised to $19 at Brookline Capital Markets

Feb 14, 2023 03:28 PM Fusion Pharmaceuticals (FUSN) PT Raised to $17 at Brookline Capital Markets

Feb 14, 2023 07:09 AM Fusion Pharmaceuticals (FUSN) PT Raised to $11 at Truist Securities

Feb 14, 2023 06:46 AM Fusion Pharmaceuticals (FUSN) PT Raised to $13 at Wedbush

Feb 13, 2023 04:06 PM Fusion Pharmaceuticals (FUSN) Announces 17.6M Share Offering at $3.40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T

Feb 13, 2023 04:04 PM Fusion Pharmaceuticals Inc. (FUSN) Halted, News Pending

Jan 27, 2023 03:24 AM Fusion Pharmaceuticals (FUSN) PT Lowered to $10 at Morgan Stanley

Jan 6, 2023 07:45 AM Fusion Pharmaceuticals Inc. (FUSN) Provides Recent Corporate Highlights

Jan 5, 2023 05:01 PM Fusion Pharmaceuticals (FUSN) and BWXT (BWXT) Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

Dec 1, 2022 05:38 AM B.Riley Resumes Fusion Pharmaceuticals (FUSN) at Buy

Nov 30, 2022 06:04 AM SVB Leerink Starts Fusion Pharmaceuticals (FUSN) at Outperform

Nov 7, 2022 04:25 PM Fusion Pharmaceuticals (FUSN) Appoints Dmitri Bobilev as Chief Medical Officer

Sep 15, 2022 04:10 PM UPDATE: Truist Securities Starts Fusion Pharmaceuticals (FUSN) at Buy

Sep 6, 2022 04:33 PM Jones Trading Starts Fusion Pharmaceuticals (FUSN) at Buy

Aug 9, 2022 02:11 PM Fusion Pharmaceuticals (FUSN) PT Lowered to $12 at Wedbush